Brind.

Recursion Pharmaceuticals and Biodexa Pharmaceuticals are developing treatments for FAP, with Biodexa in Phase 3 and Recursion in Phase 1b/2.

1 report, 1 independent Updated Jul 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Recursion (United States)

Keep exploring

The entities involved

Recursion (United States)
company in Salt Lake City, United States
- Recursion (United States) disclosed insider trading via required filings with the SEC on June 6, 2026.Sun 17:12
- Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Sun 05:14

Related events

Recursion Pharmaceuticals is listed on Nasdaq, and BioCardia, Inc. is a company developing therapeutics in the United States.Sep 7

Coverage

Newest first; wire copies grouped

Jul 28ACCESS NewswireHow Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Poly